Research programme: human monoclonal antibodies - Medarex/Trillium Therapeutics

Drug Profile

Research programme: human monoclonal antibodies - Medarex/Trillium Therapeutics

Alternative Names: Fgl2 Mab; Fgl2-specific monoclonal antibody; Human monoclonal antibodies research programme - Medarex/Trillium Therapeutics

Latest Information Update: 12 Feb 2013

Price : $50

At a glance

  • Originator Medarex; Trillium Therapeutics
  • Developer Medarex
  • Class Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Immunological disorders; Transplant rejection

Most Recent Events

  • 12 Feb 2013 Discontinued - Preclinical for Transplant rejection in USA (unspecified route)
  • 12 Feb 2013 Discontinued - Preclinical for Immunological disorders in USA (unspecified route)
  • 03 May 2007 No development reported - Preclinical for Transplant rejection in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top